Abstract:Importance The recombinant zoster vaccine (RZV) is currently recommended for immunocompetent adults aged 50 years or older and immunocompromised adults aged 19 years or older and is effective in preventing herpes zoster ophthalmicus (HZO). However, questions about the safety of RZV in patients with a history of HZO remain. Objective To evaluate whether there is an increased risk of HZO recurrence after RZV in patients with a history of HZO. Design, Setting, and Participants This retrospective cohort study used medical and outpatient pharmacy claims data for commercial and Medicare Advantage enrollees from the Optum Labs Data Warehouse. Patients with incident HZO from January 1, 2010, to December 31, 2021, were identified; the study period ended on March 31, 2022. The vaccinated group consisted of patients with at least 1 dose of RZV more than 90 days following the initial HZO diagnosis. The unvaccinated group consisted of patients without any record of RZV in the study period. Vaccinated and unvaccinated patients were matched using exact k:1 matching without replacement. Exposure Recombinant zoster vaccination. Main Outcomes and Measures The main outcome was the number of HZO recurrences with and without RZV exposure. Results A total of 16 408 patients were included in the matched analysis, of whom 12 762 were unvaccinated (7806 [61.2%] female; mean [SD] age at diagnosis, 68.8 [10.3] years) and 3646 were vaccinated (2268 [62.2%] female; mean [SD] age at diagnosis, 67.4 [9.8] years). Within the primary risk period of 56 days after the index date (ie, the start of follow-up for the outcome), the incidence of HZO recurrence after any RZV exposure was 37.7 per 1000 person-years compared with 26.2 per 1000 person-years in the unexposed group. After controlling for race and ethnicity, inpatient stays, emergency department visits, concomitant vaccines, and eye care practitioner visits, the association between vaccination status and HZO exacerbation in the primary risk period had an adjusted hazard ratio for any RZV exposure of 1.64 (95% CI, 1.01-2.67; P = .04). Conclusions and Relevance In this study, RZV exposure was associated with a higher likelihood of HZO recurrence in patients with a history of HZO compared with no RZV exposure. These findings support consideration that patients with a history of HZO may benefit from monitoring after receiving RZV in case of HZO recurrence.

Exploring the Link between Varicella-Zoster Virus, Autoimmune Diseases, and the Role of Recombinant Zoster Vaccine

Dynamic Immune Landscape and VZV-Specific T Cell Responses in Patients with Herpes Zoster and Postherpetic Neuralgia

Efficacy of varicella (VZV) vaccination: an update for the clinician

Herpes zoster: A Review of Clinical Manifestations and Management

Herpes Zoster and Cardiovascular Disease: Exploring Associations and Preventive Measures through Vaccination

Herpes zoster ophthalmicus following recombinant zoster vaccine: A case report and brief literature review

Risk of Herpes Zoster Ophthalmicus Recurrence After Recombinant Zoster Vaccination

Varicella Zoster Virus Reactivation Following COVID-19 Vaccination: A Systematic Review of Case Reports

Immunogenicity and influence on disease activity of recombinant zoster vaccine in patients with rheumatoid arthritis treated with DMARDs

Clinical Features of Varicella-Zoster Virus Infection

Immunogenicity to Herpes Zoster recombinant subunit vaccine in immune-mediated rheumatic patients under treatment with JAK inhibitors

Reactivation of Varicella Zoster Virus after Vaccination for SARS-CoV-2

Primary and Acquired Immunodeficiencies Associated With Severe Varicella-Zoster Virus Infections

Herpes zoster Reactivation After COVID-19 Vaccine with Focus on Postherpetic Neuralgia Prevention: A Case Series

Association of asthma and herpes zoster, the role of vaccination: A literature review

Issues in the Treatment of Neurological Conditions Caused by Reactivation of Varicella Zoster Virus (VZV)

Varicella-zoster virus: pathogenesis, incidence patterns and vaccination programs

A systematic review and meta-analysis of herpes zoster occurrence/recurrence after COVID-19 infection and vaccination

Healthy ageing: Herpes zoster infection and the role of zoster vaccination

Unraveling the Immune Signature of Herpes Zoster: Insights Into the Pathophysiology and Human Leukocyte Antigen Risk Profile

Herpes zoster following BNT162b2 mRNA COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series